Risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity by Chu, Thomas P.C. et al.
Risk of venous thromboembolism during and after 
hospitalisation in patients with inflammatory bowel disease
activity.
Running title: Timeliness of thromboprophylaxis in inflammatory bowel disease
Thomas P C Chu (1)
Matthew J Grainge (1)
Timothy R Card (1, 2)
(1) Division of Epidemiology and Public Health, University of Nottingham, 
Nottingham, United Kingdom.
(2) Nottingham Digestive Diseases Centre Biomedical Research Unit, University of 
Nottingham, Nottingham, United Kingdom.
Correspondence: Thomas P C Chu, thomas.chu@nottingham.ac.uk
Division of Epidemiology and Public Health, Clinical Sciences Building, Nottingham 
City Hospital, University of Nottingham, Nottingham NG5 1PB. Tel: 0115 823 1346
Main text (introduction to conclusions): 3,692 words.
1
Acknowledgements
This study was made possible by a grant from Crohn’s and Colitis UK. This work 
uses data provided by patients and collected by the National Health Service in the 
United Kingdom as part of their care and support.
Ethical approval for the use of data from Clinical Practice Research Datalink (formerly
General Practice Research Database) in this study has been given by their 
Independent Scientific Advisory Committee (reference number 10_147).
2
SUMMARY
Background
Inflammatory bowel disease (IBD) increases the risk of venous thromboembolism.
Aim
To determine when patients are at high risk of thromboembolic events, including after
major surgery, and to guide timing of thromboprophylaxis.
Methods
Each inflammatory bowel disease patient from Clinical Practice Research Datalink, 
linked with Hospital Episode Statistics, was matched to up to five non-IBD patients in 
this cohort study. We examined their risk of thromboembolism in hospital and within 
six weeks after leaving hospital, with or without undergoing major surgery, and while 
ambulant. Hazard ratios were estimated using Cox regression, with adjustment for 
age, sex, body mass index, smoking and history of malignancy or thromboembolism.
Results
Overall 23,046 inflammatory bowel disease patients had a thromboembolic risk 1.74 
times (95% CI = 1.55–1.96) higher than 106,795 non-IBD patients. Among ambulant 
patients, the thromboembolic risk was raised during acute (hazard ratio = 3.94, 2.79–
5.57) or chronic disease activity (3.97, 2.90–5.45) but their absolute risk remained 
below 5/1000 person-years. The hazard ratio for thromboembolism among in-patients
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not undergoing major surgery was 1.13 (0.63–2.02), compared to 2.43 (1.20–4.92) 
among surgical patients, with a near doubling of absolute risk associated with 
surgery (59.5/1000 person-years, compared with 31.1 without surgery). The absolute 
risk remained elevated within six weeks after leaving hospital (18.6/1000 person-
years in inflammatory bowel disease patients after surgery).
Conclusions
Inflammatory bowel disease patients are at an increased risk of venous 
thromboembolism. Absolute risks are raised during active disease, when in hospital, 
and after leaving hospital following major surgery.
MeSH keywords: inflammatory bowel diseases, embolism and thrombosis, 
hospitalization, risk factors
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INTRODUCTION
Venous thromboembolism is a recognised complication of inflammatory bowel 
diseases (IBD).[1–3] It is associated with morbidity and mortality that are potentially 
avoidable with prophylaxis.[4] Thromboprophylaxis is not free of risk, cost or 
discomfort.
It is recognised that prophylaxis is justified by the size of thromboembolic risk among 
hospitalised inflammatory bowel disease patients, which leads to widespread 
acceptance that this should be routine.[5–8] We demonstrated that the risk of venous
thromboembolism is also increased in ambulant inflammatory bowel disease 
patients, and the risk is higher in periods of bowel inflammation.[9] Our work did not 
demonstrate any additional period in which prophylaxis may be justified.
However, we were unable to elucidate the precise time periods when inflammatory 
bowel disease patients were at high risk of thromboembolic events due to limitations 
of the data, and we had to estimate the dates of hospital admission and discharge 
from general practice records.[9] We have since been able to obtain primary care 
records (Clinical Practice Research Datalink), linked to hospital records (Hospital 
Episode Statistics), and this enabled us to re-examine this issue using methodology 
from other studies investigating the association between venous thromboembolism 
and diseases using linked data.[10–12] Over the same period, it has become 
standard practice to extend thromboprophylaxis in patients undergoing major surgery
for abdominal or pelvic cancers to up to 28 days after surgery.[13] We have therefore 
revisited the question of when inflammatory bowel disease patients are at an 
increased risk of thromboembolic events, defining admission and surgery dates using
5
hospital records, and have also examined the period after leaving hospital when the 
effect of extended prophylaxis may occur.
MATERIALS and METHODS
Data sources
We identified a cohort of inflammatory bowel disease patients with a diagnosis of 
Crohn's disease, ulcerative colitis or indeterminate colitis recorded in Clinical Practice
Research Datalink (previously known as the General Practice Research Database) 
consultation records between January 1987 and January 2011. We obtained linked 
records from Hospital Episode Statistics on in-patient stays between 1st April 1997 
and 31st October 2010 and linked death records between 1st January 1998 and 10th
January 2012 from the Office for National Statistics.
Clinical Practice Research Datalink (CPRD) is one of the world’s largest databases of
longitudinal primary care records. Over 600 practices, covering around 7% of the UK 
population, have been contributing data on primary care events such as 
consultations, symptoms and diagnoses, investigations and prescriptions. CPRD 
audits data from each practice and assigns an “up-to-standard” date, after which 
records are judged to be of acceptable standard for research. A primary care practice
is designated as “up-to-standard” when the quality of the data it contributes meet the 
minimum quality criteria. Patient records after the “up-to-standard” date should not 
contain any significant gaps in their data and the recording of deaths or when 
patients left a practice is accurate.[14] These data are linked for a subset of practices
to other data sources allowing enrichment of the data. The quality of data on 
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inflammatory bowel disease and diagnoses of venous thromboembolism has also 
been validated externally.[10,15,16]
Hospital Episode Statistics (HES) contains routine records on clinical care (e.g. date 
of beginning and end of each episode, main and other diagnoses, surgical 
procedures, etc.) of in-patient stays at National Health Service hospitals in England.
[17] Dates and the nature of clinical care received by each patient are recorded in 
medical notes by the medical team and coded at the end of each episode to become 
part of the data. The HES data quality team publish data quality reports with each 
release.[18]
Patients
We matched each inflammatory bowel disease patient by sex and date of birth (within
one year) to up to five non-IBD patients within the same primary care practice. If only 
the month or the year was available, the date of birth was assumed to be on the 15th 
day of the month or on 1st July. To ensure some overlap in observation time existed 
for each group of matches, we picked non-IBD patients so that the index date of each
inflammatory bowel disease patient (defined as the later of the date entering CPRD 
or date of the earliest record of an inflammatory bowel disease diagnosis) fell 
between the dates entering and leaving CPRD in non-IBD patients. The date entering
CPRD was the later of the patient’s current registration date or “up-to-standard” date 
of the practice, and the date leaving CPRD was the earliest of the patient’s transfer-
out date, date of death or the last data collection date of the practice.
Outcome event
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The outcome event was the first record of pulmonary embolism (International 
Classification of Diseases, 10th revision: I26), lower limb deep vein thrombosis or 
other deep vein thrombosis (I80 to I82) in Clinical Practice Research Datalink or 
Hospital Episode Statistics, verified by one of: an anticoagulant prescription within 90
days, evidence of anticoagulation on the basis of medical records within 90 days, or 
death from any cause within 30 days of a thromboembolic event. This definition has 
been validated in Clinical Practice Research Datalink.[15]
Patients were considered at risk of the outcome from the later of the index date or the
date our data began. They were no longer considered at risk after the end of data or 
after the first instance of the outcome, whichever was earlier.
At-risk periods
We divided phases of inflammatory bowel disease activity as “acute” (or “flare”), 
“chronic” or “in remission”. An “acute” phase began with issuance of a new 
corticosteroid prescription or a record of in-patient admission with Crohn's disease 
(International Classification of Diseases, 10th revision: K50) or ulcerative colitis (K51)
as the main diagnosis following a period of remission. Patients continuing to receive 
corticosteroids beyond the first 120 days after a flare had started (i.e. the “acute” 
phase) entered a “chronic” phase, which lasted until 120 days after the last 
corticosteroid prescription. The remission period started 120 days after the last 
corticosteroid prescription or IBD-related hospital admission.[9]
Hospitalisation status was classified into “in-patient”, “after discharge” and 
“ambulatory”. The “after discharge” period lasted for six weeks following the date 
when a patient left hospital. Though thromboembolic events that occur sooner after 
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leaving hospital are more likely to be attributable to the in-patient stay, the “after 
discharge” period must also be long enough so that a reasonable number of events 
can accrue for analysis. Our choice of six weeks was a compromise between these 
requirements and any length from 28 to 90 days used by other authors.
Statistical analysis
We estimated the ratio of  occurrence (hazard ratios) of venous thromboembolism 
between inflammatory bowel disease and non-IBD patients in a Cox proportional 
hazards model, with adjustment for age, sex, body mass index (averaged over all the
records of each patient), tobacco use, history of malignancy and previous 
thromboembolic events. Tobacco use was categorised as, from high to low, “current”, 
“ex-smoker”, “not current” or “unknown” based on the highest recorded level.
We further investigated the contribution of inflammatory bowel disease activity and in-
patient stays to the risk of venous thromboembolism in time-varying Cox proportional 
hazards models, to incorporate temporal changes in inflammatory bowel disease 
severity and hospital use status, and in a self-controlled case series analysis, in 
which we used data from individuals who had a thromboembolic event and at 
different phases of inflammatory bowel disease activity.[19,20] We illustrated 
temporal changes in the cumulative hazard of thromboembolic events, in which the 
risk of venous thromboembolism in each period was represented by the gradient of 
each curve.[21]
In the self-controlled case series analysis, we examined the strength of association 
between an outcome, a thromboembolic event, and time-varying exposures such as 
different periods of hospital stays and inflammatory bowel disease activity. This 
9
analysis used records from patients who experienced a thromboembolic event during
the observation period, and compared the probability that a thromboembolic event 
occurred in periods when patients were exposed (for example, during hospital stays) 
to unexposed (for example, while ambulatory).[19,20] This approach estimates the 
change in the risk of venous thromboembolism in patients when their exposure status
changes with time.
Analyses were carried out in Stata and in the R statistical language.[22]
RESULTS
We identified from Clinical Practice Research Datalink a cohort comprising 23,046 
inflammatory bowel disease patients matched to 106,795 non-IBD patients, after 
excluding inflammatory bowel disease patients without any linked records from 
Hospital Episode Statistics (n = 33,028) or patients who left CPRD before their 
primary care practices were able to provide “up-to-standard” data (n = 2,922). The 
large proportion of patients with no linked records from Hospital Episode Statistics 
was within expectation, since only half of primary care practices had consented to 
record linkage at the time of this study and assuming a linkage success of 80%.
Among patients with a thromboembolic event, inflammatory bowel disease patients 
(mean = 55.0 years, 40.2% were 41–60 year-olds) were younger than non-IBD 
patients (mean = 59.4 years, 43.2% were 61–80 year-olds). Inflammatory bowel 
disease patients also had lower body mass indices (Table 1). Patients with a 
thromboembolic event were also more likely to have a previous event: 20.5% had a 
previous thromboembolic event in inflammatory bowel disease patients, which was 
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more than double the proportion in non-IBD patients (9.1%). The proportion of 
patients with a history of malignancy was similar for inflammatory bowel disease 
(16.6%) and non-IBD patients (14.2%) who did not have any thromboembolic events.
In patients who had a thromboembolic event, 26.5% of inflammatory bowel disease 
patients and 30.8% of non-IBD patients had a history of malignancy.
Overall risk of a thromboembolic outcome
The overall risk of venous thromboembolism in inflammatory bowel disease patients 
was 74% higher than in non-IBD patients (hazard ratio, HR = 1.74, 95% CI = 1.55–
1.96) from Cox proportional hazards models (Table 2 and Figure 1). The risk of 
venous thromboembolism varied with inflammatory bowel disease activity: it rose to 
four times as high as in non-IBD patients (HR = 4.02, 95% CI = 3.08–5.25) during an 
acute episode, and fell slightly when the inflammatory process entered the chronic 
phase (HR = 3.71, 95% CI = 2.87–4.79). During remission, thromboembolism risk 
remained at 39% higher than in non-IBD patients (95% CI = 1.21–1.60). In 
inflammatory bowel disease patients, analysed using the self-controlled case series 
method to eliminate all time stable confounding, the thromboembolism risk during 
chronic phase was 2.64 times (95% CI = 1.76–3.96) the risk when in remission, 
which was similar to the risk of thromboembolism during the acute phase (rate ratio, 
RR = 2.37, 95% CI = 1.71–3.29) (Table 3 and Figure 2).
During in-patient stays
The absolute risk of venous thromboembolism during an in-patient stay (28.1 per 
1,000 person-years in non-IBD and 59.5 in inflammatory bowel disease patients after
major surgery; 30.3 in non-IBD and 31.1 in inflammatory bowel disease without major
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surgery) was higher than after leaving hospital (19.7 in non-IBD and 18.6 in 
inflammatory bowel disease after major surgery; 15.6 in non-IBD and 12.3 in 
inflammatory bowel disease without major surgery) and during ambulatory periods 
(1.1 in non-IBD and 2.0 in inflammatory bowel disease) (Table 2 and Figure 3). The 
risk of thromboembolism was similar between inflammatory bowel disease and non-
IBD patients not undergoing any major surgery (HR = 1.13, 95% CI = 0.63–2.02), but
very few thromboembolic events occurred in each of three phases of inflammatory 
bowel disease activity (Table 2 and 3). In patients undergoing major surgery, the risk 
of thromboembolism was higher in inflammatory bowel disease patients than in non-
IBD patients (HR = 2.43, 95% CI = 1.20–4.92).
Within six weeks after discharge
The thromboembolism risk was similar between inflammatory bowel disease and 
non-IBD patients after major surgery (HR = 1.01, 95% CI = 0.67–1.52) and also after 
admissions not involving major surgery (HR = 1.03, 95% CI = 0.77–1.37) (Table 2). 
The risk of thromboembolism was not found to vary with inflammatory bowel disease 
activity after leaving hospital (Table 3).
While ambulatory
Inflammatory bowel disease patients were at a higher risk of venous 
thromboembolism than non-IBD patients while ambulatory (HR = 1.71, 95% CI = 
1.48–1.98) (Table 2). The highest risk was during the acute phase (HR = 3.94, 95% 
CI = 2.79–5.57) and chronic phase of inflammatory bowel disease activity (HR = 
3.97, 95% CI = 2.90–5.45). The risk of thromboembolism fell during remission, but 
remained at 38% higher than non-IBD patients (95% CI = 1.17–1.63). Among 
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inflammatory bowel disease patients, thromboembolism risk was higher than in 
remission during both acute phase (RR = 2.64, 95% CI = 1.76–3.95) and chronic 
phase of inflammatory bowel disease activity (RR = 3.05, 95% CI = 1.94–4.80) (Table
3).
DISCUSSION
We have demonstrated inflammatory bowel disease patients were at a higher risk of 
venous thromboembolism – 74% greater than non-IBD patients (overall adjusted HR 
= 1.74, 95% CI = 1.55–1.96). Consistent with our previous study, thromboembolism 
risk was found to be raised when inflammatory bowel disease was active and 
remained so while ambulant, and the period of elevated risk not confined only to in-
patient episodes.[9] We have also shown the risk of thromboembolic events was 
higher during in-patient episodes involving major surgery, which persisted for a 
number of weeks after leaving hospital.
Strengths and weaknesses
This study has strengths and weaknesses inherent to the use of routinely collected 
data. By using anonymised data, we have forfeited the ability to verify the accuracy of
individual patient's clinical records. This is not a major drawback since the exposure 
status (inflammatory bowel disease) central to our study and its outcome (venous 
thromboembolism) have been demonstrated to be reliably recorded in the data we 
used.[15,16] The data we used are incomplete in some variables, and for example, 
completeness of data on body mass index and tobacco use (around 15% and 5% 
with unknown status) cannot be improved further and self-reported tobacco use 
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history cannot be verified because of anonymisation. This misclassification and 
residual confounding may lead to biased estimation of their effects on the risk of 
thromboembolic events. We have repeated our analyses, but without adjustment for 
these variables, and found the estimated effects were similar to those presented. 
This implied tobacco use and body mass index did not have a role in determining 
thromboembolism risk which was as important as one may expect. Additionally, we 
have used the self-controlled case series method to remove any confounding effect 
of variables whose values were stable within the observation period (eg. tobacco use
and body mass index), and results from this method were consistent with those from 
the Cox proportional hazards models.
Ascertainment error may have affected our assessment of disease activity similarly. 
Since acute inflammatory bowel disease episodes were defined based on 
corticosteroid prescriptions, we could have omitted milder exacerbations that were 
managed by increasing the dosage of aminosalicylates, and potentially, courses of 
corticosteroids prescribed exclusively in secondary care. We attempted to avoid the 
latter situation by accepting hospital admission for inflammatory bowel disease as 
evidence of an acute episode. This means our results reflect only inflammatory 
activity that was severe enough to require corticosteroids or a hospital stay, and 
misclassification would inevitably be present. Misclassification error was unlikely to 
be differential between patients with and without an thromboembolic event, and we 
would therefore not expect a bias other than a reduction in the estimated effects. We 
have no access to hospital prescription records, and thus unable to determine 
whether in-patient thromboprophylaxis was given. Since routine thromboprophylaxis 
is recommended in the national guidelines, we have assumed that it was offered 
universally. Hence our estimated effects represented the in-patient risk of 
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thromboembolism despite prophylaxis. Until access to linked in-patient prescriptions 
becomes possible, this remain unfortunately unproven.
Use of routinely collected data of such size and richness of data items has allowed 
sufficient subdivision of observation time to meet our aims and to provide reliable 
data on many potential confounders of the relationship we examined. Since 
exposures and outcomes are recorded independently for reasons unconnected to our
research, there is limited opportunity for information bias. Selection bias should also 
not be a problem because we have selected inflammatory bowel disease patients 
and their controls based only on their inflammatory bowel disease diagnosis and 
demographics from population-based data. Since Clinical Practice Research Datalink
is representative of the UK population, our results should therefore be generalisable 
to that population, and arguably to other similar populations.[14]
Our findings in the context of existing knowledge
It is generally recognised that inflammatory bowel disease patients are at an 
increased risk of thromboembolic events – between 1.5- and 3.5-fold increase 
overall.[2,3] Our estimates are in line with this, and likewise, our finding that the risk 
of venous thromboembolism is connected to inflammatory bowel disease activity 
accords with our previous study and with another study showing many IBD-related 
thromboembolic events occur in periods of intense disease activity.[9,23] We used 
corticosteroid prescription as a proxy for disease activity, and other studies have 
suggested a more direct role for corticosteroids.[24] Our estimation of 
thromboembolism risk in ambulatory patients with active inflammatory bowel disease 
is lower than in our previous study, perhaps suggesting bias from previous 
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misclassification of at-risk periods.[9] We estimated hospital admission and discharge
dates from general practice records previously, whereas we had accurate information
from hospital data in this study. It may be possible that in-patient periods in our 
previous study were more likely to be misclassified as ambulant in periods of active 
or chronic inflammatory bowel disease activity than in remission, leading to biased 
estimation of the risk of thromboembolism in ambulatory periods. This may also 
explain why, contrary to the results from our previous study, the risks of 
thromboembolism in acute and chronic phases of inflammatory bowel disease 
appeared to be similar.
New findings from this study include the effect of surgery on the risk of venous 
thromboembolism and the prolonged at-risk period after leaving hospital. We are by 
no means the first to recognise patients undergoing surgery are at a greater risk of 
thromboembolic events among inflammatory bowel disease or non-IBD patients. 
Surgery has long been recognised as a risk factor irrespective of inflammatory bowel 
disease.[25] More specific data on surgery in inflammatory bowel disease patients 
are also available – the odds of thromboembolism associated with elective colectomy
were 3.7 times and with emergency colectomy 5.3 times that in ulcerative colitis 
patients receiving medical therapy alone.[26] It is therefore unsurprising that 
inflammatory bowel disease patients undergoing major surgery had some of the 
highest thromboembolism risk during in-patient episodes and after leaving hospital. 
However, our findings on the effect of surgery on venous thromboembolism after 
leaving hospital are not entirely consistent with the recent literature. Surgical 
admission is not related to the risk of thromboembolic events after correcting for 
confounding factors in a recent case-control study that has included in-patient 
thromboprophylaxis data.[27] We have no access to data on in-patient prescription 
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and are thus unable to exclude the possible effect of thromboprophylaxis. However 
since in-patient thromboprophylaxis is part of the standard care in both IBD-related 
surgical and non-surgical admissions, the differences we have found are unlikely to 
be attributable to this practice.[28] Thus, our finding of high risk of venous 
thromboembolism in the first six weeks after leaving hospital following  surgery for 
inflammatory bowel disease is valid notwithstanding this limitation of our data.
Prophylaxis against venous thromboembolism
Our aim was to estimate, more accurately, the absolute risk of venous 
thromboembolism in different phases of inflammatory bowel disease activity, with a 
view to better support decision-making of when thromboprophylaxis is likely to be 
appropriate. The risk of thromboembolic events increases to 1.5–3 times the 
background risk after air travel in the general population, 3–5 times during pregnancy
and puerperium and 4–7 times in persons taking oral contraceptives.[29] The 4-fold 
increase in thromboembolism risk associated with acute or chronic inflammatory 
bowel disease activity while ambulatory (4.9 per 1,000 person-years) would therefore
not be a sufficient reason for routine prophylaxis against venous thromboembolism 
among inflammatory bowel disease patients.
The risk of thromboembolism is substantially higher in both inflammatory bowel 
disease and non-IBD patients while in hospital, especially after major surgery (close 
to 30 per 1,000 person-years). The current consensus is to offer prophylaxis to in-
hospital inflammatory bowel disease patients until they are ambulant, and it is 
important to recognise much of the risk has been reduced by such prophylaxis.[4,30–
32]
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In recent years there has been a growing body of evidence on the persistence of the 
risk of thromboembolism after leaving hospital for major surgery and the potential for 
a longer period of prophylaxis. Extension of thromboprophylaxis has been shown to 
be safe and efficacious, especially after surgery for colorectal cancer.[33–35] This 
has become routine practice and is now recommended in national guidelines.[13] We
have found that the risk of a thromboembolic event persists after surgery in 
inflammatory bowel disease patients for some time after leaving hospital. This is also 
supported by another study showing an excess  risk of venous thromboembolism in 
those undergoing emergency surgery.[36] The size of the risk of thromboembolism 
we found is consistent with other patients after major surgery, suggesting similar 
post-operative risks in inflammatory bowel disease patients and in patients 
undergoing surgery for colorectal cancer.[36–38]
Conclusions
 We found inflammatory bowel disease patients have a 1.75-fold increase in the risk 
of thromboembolism overall, and that the absolute risk is highest during hospital 
admissions especially after surgery. We have confirmed patients outside hospital 
have a higher risk when their inflammatory bowel disease is active, but the size of the
absolute risk does not warrant routine thromboprophylaxis. We have also shown that 
inflammatory bowel disease patients remain at high risk of thromboembolic events 
after leaving hospital for surgery, and their absolute risk is similar to other patients 
undergoing major surgery. Our findings suggest that the current focus on 
thromboprophylaxis in hospitalised inflammatory bowel disease patients is 
appropriate, but raises the question on whether it should be extended to the period 
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after leaving hospital for inflammatory bowel disease patients as it is for colorectal 
cancer patients.
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Tables
Table 1: Distribution of patient demographics, by inflammatory bowel disease (IBD) 
and venous thromboembolism (VTE) status.
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No VTE (N = 128,346) Developed VTE (N = 1,495)
Non-IBD
patients IBD patients
Non-IBD
patients IBD patients
n % n % n % n %
Total 105,730 22,616 1,065 430
Male 49,879 47.2 10,620 47.0 469 44.0 198 46.0
Mean age 
(years) 48.0 48.1 59.4 55.0
Age group 
(years)
0–20 5,000 4.7 1,041 4.6 7 0.7 5 1.2
21–40 34,714 32.8 7,518 33.2 130 12.2 79 18.4
41–60 36,482 34.5 7,718 34.1 379 35.6 173 40.2
61–80 24,234 22.9 5,153 22.8 460 43.2 148 34.4
over 80 5,300 5.0 1,186 5.2 89 8.4 25 5.8
History of VTE 1,634 1.5 589 2.6 97 9.1 88 20.5
History of 
cancer 15,012 14.2 3,745 16.6 328 30.8 114 26.5
Body mass 
index
0–18.5 2,693 2.5 808 3.6 14 1.3 7 1.6
18.5–25.0 39,013 36.9 9,422 41.7 281 26.4 135 31.4
25.0–30.0 29,930 28.3 6,470 28.6 360 33.8 147 34.2
30.0–50.0 15,697 14.8 3,060 13.5 294 27.6 95 22.1
Unknown 18,397 17.4 2,856 12.6 116 10.9 46 10.7
Tobacco use
Non-current 49,280 46.6 10,456 46.2 482 45.3 184 42.8
Current 32,704 30.9 6,574 29.1 316 29.7 110 25.6
Ex-smoker 16,240 15.4 4,726 20.9 237 22.3 124 28.8
Unknown 7,506 7.1 860 3.8 30 2.8 12 2.8
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Table 2: Estimated hazard ratios, from time-varying Cox models, of the risk of a 
venous thromboembolic event (VTE) at different periods of inflammatory bowel 
disease (IBD) activity and hospitalisation, when compared to non-IBD patients in 
identical situations.
Hazard ratios were adjusted for age, sex, body mass index, tobacco use, history of 
cancer and history of venous thromboembolism.
CI = confidence interval, p-y = person-years.
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VTE events
Follow-up Incidence rate Hazard ratio 95% CI
(person-years)(1,000 p-y) (adjusted)
All periods combined
Non-IBD patients 970 630,041.2 1.5 1.00
IBD patients 383 135,972.4 2.8 1.74 1.55– 1.96
Acute 58 9,763.7 5.9 4.02 3.08– 5.25
Chronic 63 9,763.5 6.5 3.71 2.87– 4.79
Remission 262 116,445.3 2.2 1.39 1.21– 1.60
Inpatient, no major surgery
Non-IBD patients 40 1,318.9 30.3 1.00
IBD patients 16 513.9 31.1 1.13 0.63– 2.02
Acute 3 87.2 34.4 1.66 0.51– 5.36
Chronic 4 78.5 51.0 1.93 0.69– 5.41
Remission 9 348.3 25.8 0.88 0.43– 1.81
Inpatient, had major surgery
Non-IBD patients 15 533.0 28.1 1.00
IBD patients 16 268.7 59.5 2.43 1.20– 4.92
Acute 3 55.6 53.9 3.26 0.94– 11.29
Chronic 1 44.5 22.5 1.06 0.14– 8.02
Remission 12 168.6 71.2 2.55 1.19– 5.44
Within 6 weeks after discharge, no major surgery
Non-IBD patients 145 9,323.7 15.6 1.00
IBD patients 70 5,676.0 12.3 1.03 0.77– 1.37
Acute 15 1,314.8 11.4 1.12 0.66– 1.91
Chronic 12 1,041.8 11.5 1.08 0.60– 1.95
Remission 43 3,319.3 13.0 0.98 0.70– 1.39
Within 6 weeks after discharge, had major surgery
Non-IBD patients 97 4,912.2 19.7 1.00
IBD patients 31 1,666.8 18.6 1.01 0.67– 1.52
Acute 3 199.4 15.0 1.00 0.32– 3.15
Chronic 5 179.0 27.9 1.62 0.66– 3.99
Remission 23 1,288.5 17.9 0.94 0.59– 1.48
Ambulatory
Non-IBD patients 673 613,953.4 1.1 1.00
IBD patients 250 127,847.1 2.0 1.71 1.48– 1.98
Acute 34 8,106.6 4.2 3.94 2.79– 5.57
Chronic 41 8,419.8 4.9 3.97 2.90– 5.45
Remission 175 111,320.6 1.6 1.38 1.17– 1.63
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Table 3: Estimated incidence rate ratios, from self-controlled case series analysis, of 
the risk of a venous thromboembolic event (VTE) at different periods of inflammatory 
bowel disease activity, in different periods of hospitalisation.
CI = confidence interval.
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VTE
events Rate ratio 95% CI
All periods combined
Remission 1,233 1.00
Acute 58 2.37 1.71– 3.29
Chronic 63 2.64 1.76– 3.96
Inpatient, no major surgery
Remission 49 1.00
Acute 3 1.13 0.33– 3.93
Chronic 4 1.96 0.64– 5.98
Inpatient, had major surgery
Remission 27 1.00
Acute 3 1.03 0.28– 3.77
Chronic 1 0.68 0.09– 5.33
Within 6 weeks after discharge, no major surgery
Remission 188 1.00
Acute 15 0.97 0.55– 1.72
Chronic 12 1.01 0.51– 2.01
Within 6 weeks after discharge, had major surgery
Remission 120 1.00
Acute 3 0.64 0.19– 2.13
Chronic 5 1.45 0.54– 3.88
Ambulatory
Remission 849 1.00
Acute 34 2.64 1.76– 3.95
Chronic 41 3.05 1.94– 4.80
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Figure legends
Figure 1: Cumulative hazard curves of venous thromboembolic events among 
inflammatory bowel disease patients (broken line) and non-IBD patients (solid line) in
the entire observation time.
The gradient of each line represents the risk of venous thromboembolism.
Figure 2 left: Cumulative hazard curves of venous thromboembolic events from the 
beginning of different time periods in non-IBD patients (black) and inflammatory 
bowel disease patients: acute phase inflammatory bowel disease (red), chronic 
(purple), in remission (blue).
Figure 2 right: Same as Figure 2 left, focusing on events occurring up to 180 days 
from the beginning of each time period.
Figure 3 left: Cumulative hazard curves of venous thromboembolic events up to 180 
days from the beginning of different time periods in inflammatory bowel disease 
patients: ambulatory (black), in-patient stays (red) and within six weeks after leaving 
hospital (purple), after major surgery (broken lines) or without undergoing major 
surgery (solid lines).
Figure 3 right: Same as Figure 3 left, focusing on events occurring up to 42 days 
from the beginning of each time period.
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